IGIlaria Gori

Ilaria Gori

*This is an algorithmically generated author record based on publicly available information.

Ilaria Gori has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multimodal population-scale cell atlases define archetypes and extremes of human blood

    by Olli Dufva, Shuang Li, J. Patrick Pett, Arianna Landini, Daniela Zanotti, Lisa Dratva, Lorenz Kretschmer, Krzysztof Polanski, Chuan Xu, Ioannis Sarropoulos, et al.

    The cellular composition of blood is fundamental to human physiology and is routinely measured to assess health and disease. Circulating immune cells show extensive heterogeneity, but the organising principles and extremes of variation across individuals remain undefined. Here, using single-cell transcriptomics across two biobank cohorts encompassing ~6,000 individuals, we show that human blood occupies recurrent archetypal states defined by coordinated cell composition patterns. We delineate three major archetypes spanning naive lymphoid, myeloid and cytotoxic composition, and two minor archetypes characterised by type I interferon-driven inflammation and expanded premalignant CD5+ B cells. We develop cell2clone to infer lymphocyte clonal expansions, revealing how reactive clonal processes drive the cytotoxic archetype and premalignant clonal expansion establishes the CD5+ B cell archetype, creating outlier states that uncover context-specific effects of germline variants. Clonal haematopoiesis and mosaic chromosomal alterations influence blood states in an archetype-dependent manner. The archetype framework links blood states to common disease risk and clinical blood counts and, through a machine-learning model ArcheTypist, classifies infection and cancer immunotherapy outcomes. This population-scale framework has implications for diagnostics, early disease detection, immunotherapy stratification and mechanistic insights into disease susceptibility and therapy response, providing an organising model for identifying compositional subtypes across human tissues.

  • Open Access

    Pathogenic ACVR1R206H activation by Activin A‐induced receptor clustering and autophosphorylation

    by Anassuya Ramachandran, Merima Mehić, Laabiah Wasim, Dessislava Malinova, Ilaria Gori, Beata K Blaszczyk, Diana M Carvalho, Eileen M Shore, Chris Jones, Marko Hyvönen, et al.

    Fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG) are debilitating diseases that share causal mutations in ACVR1, a TGF‐β family type I receptor. ACVR1 R206H is a frequent mutation in both diseases. Pathogenic signaling via the SMAD1/5 pathway is mediated by Activin A, but how the mutation triggers aberrant signaling is not known. We show that ACVR1 is essential for Activin A‐mediated SMAD1/5 phosphorylation and is activated by two distinct mechanisms. Wild‐type ACVR1 is activated by the Activin type I receptors, ACVR1B/C. In contrast, ACVR1 R206H activation does not require upstream kinases, but is predominantly activated via Activin A‐dependent receptor clustering, which induces its auto‐activation. We use optogenetics and live‐imaging approaches to demonstrate Activin A‐induced receptor clustering and show it requires the type II receptors ACVR2A/B. Our data provide molecular mechanistic insight into the pathogenesis of FOP and DIPG by linking the causal activating genetic mutation to disrupted signaling.


  • Open Access

    Mutations in SKI in Shprintzen–Goldberg syndrome lead to attenuated TGF-β responses through SKI stabilization

    by Ilaria Gori, Roger George, Andrew G Purkiss, Stephanie Strohbuecker, Rebecca A Randall, Roksana Ogrodowicz, Virginie Carmignac, Laurence Faivre, Dhira Joshi, Svend Kjær, et al.

    Shprintzen–Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys–Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-β signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional co-repressor SKI, which is a negative regulator of TGF-β signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing, and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This results in stabilization of SKI and consequently attenuation of TGF-β responses, both in knockin cells expressing an SGS mutation and in fibroblasts from SGS patients. Thus, we reveal that SGS is associated with an attenuation of TGF-β-induced transcriptional responses, and not enhancement, which has important implications for other Marfan-related syndromes.